Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · IEX Real-Time Price · USD
1.630
-0.010 (-0.61%)
At close: Jul 19, 2024, 4:30 PM
1.550
-0.080 (-4.91%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Processa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for PCSA stock have an average target of 6.00, with a low estimate of 4.00 and a high estimate of 8.00. The average target predicts an increase of 268.10% from the current stock price of 1.63.
Analyst Consensus: Buy
* Price targets were last updated on Jun 12, 2024.
Analyst Ratings
The average analyst rating for PCSA stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
Buy | 2 | 3 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 4 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +390.80% | Jun 12, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +390.80% | May 13, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +390.80% | Apr 25, 2024 |
Benchmark | Benchmark | Buy Reiterates $4 | Buy | Reiterates | $4 | +145.40% | Mar 6, 2024 |
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 17, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.98
from -8.48
EPS Next Year
-2.15
from -3.98
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | 12.6M | 51.5M |
Avg | n/a | n/a | n/a | 6.1M | 46.8M |
Low | n/a | n/a | n/a | n/a | 42.0M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 740.7% |
Avg | - | - | - | - | 665.1% |
Low | - | - | - | - | 585.5% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -4.10 | -2.22 | -6.51 | -5.67 | 13.23 |
Avg | -3.98 | -2.15 | -6.32 | -5.51 | 12.85 |
Low | -3.82 | -2.07 | -6.08 | -5.29 | 12.35 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.